AR and posterior cortical atrophy: In preclinical studies, EPI-001 significantly reduced the growth of LNCaP-95 cells, an androgen-independent and enzalutamide-resistant PCa line expressing both AR-FL and AR-V7, in vitro and in vivo [21].